Clinical Trials in Nebraska for Adults - 18

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1

Using VR to Assess the Efficacy of a Motivational Interviewing Intervention to Increase Bystander Behaviors
NCT04160702
Condition: Sexual Assault
Intervention: Behavioral: Motivate-The-Bystander (MTB)
Sponsors: University of Nebraska Lincoln; University of Nebraska
Recruiting
Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects
NCT04138836
Condition: Healthy Participants
Interventions: Drug: BBT-877; Drug: Midazolam; Drug: Itraconazole; Drug: Esomeprazole
Sponsors: Bridge Biotherapeutics, Inc.; KCRN Research, LLC
Active, not recruiting
A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OTAP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
NCT04121078
Condition: Healthy Volunteers
Interventions: Drug: TAK-906; Drug: Rifampin
Sponsor: Millennium Pharmaceuticals, Inc.
Completed
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
NCT04092712
Condition: Healthy Volunteers
Intervention: Drug: [14C]-CTP-543
Sponsors: Concert Pharmaceuticals; Celerion
Completed
Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects
NCT04044339
Condition: Healthy
Interventions: Drug: TD-5202; Drug: Placebo
Sponsor: Theravance Biopharma
Completed
Comparison of a Non-linear Analysis of Balance During the mBESS to the Sway Balance Application
NCT03994952
Condition: Healthy Volunteers
Interventions: Device: Sway Balance Application; Device: Balance Tracking Systems
Sponsor: University of Nebraska
Recruiting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects
NCT03830125
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: BBT-877, Single dose; Drug: Placebo group; Drug: BBT-877, Multiple doses
Sponsors: Bridge Biotherapeutics, Inc.; KCRN Research, LLC
Recruiting
A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants
NCT03706469
Condition: Healthy Volunteers
Interventions: Drug: TAK-831 T2; Drug: TAK-831 T3
Sponsor: Millennium Pharmaceuticals, Inc.
Completed
To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers
NCT03543137
Condition: Tobacco Use Disorder
Interventions: Drug: Nicotine Prototype Mini lozenge; Drug: Nicorette Mini Lozenge
Sponsor: GlaxoSmithKline
Completed
Drug-Drug Interaction (DDI) Study for TD-9855
NCT03432793
Condition: Drug Drug Interaction (DDI)
Interventions: Drug: TD-9855; Drug: Fluvoxamine; Drug: Itraconazole; Drug: Caffeine
Sponsor: Theravance Biopharma
Completed
TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
NCT03408470
Conditions: Intestinal Disorders; Bowel Diseases, Inflammatory
Interventions: Drug: TD-1473 oral capsule; Drug: [14C]-TD-1473 IV bolus; Drug: [14C]-TD-1473 Oral Capsule
Sponsor: Theravance Biopharma
Completed
Finances First: A Health Intervention in Low Income Single Mother Households
NCT03035240
Condition: Financial Stress
Intervention: Behavioral: Financial Education
Sponsor: Creighton University
Recruiting
Effect of Caloric Restriction and Protein Intake on Metabolism and Anabolic Sensitivity
NCT02945410
Conditions: Weight Loss; Starvation
Interventions: Other: Caloric Restriction; Other: Protein; Other: Exercise; Dietary Supplement: Calcium and Vitamin D; Other: Maltodextrin
Sponsor: University of Nebraska Lincoln
Completed
TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
NCT02772159
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: TD-4208
Sponsor: Theravance Biopharma
Completed
SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects
NCT02657122
Condition: Healthy
Interventions: Drug: TD-1473 for SAD; Drug: Placebo for SAD; Drug: TD-1473 for MAD; Drug: Placebo for MAD
Sponsor: Theravance Biopharma
Completed
Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center
NCT02409147
Condition: Uterus Transplant
Intervention: Procedure: Uterine Transplant
Sponsor: University of Nebraska
Withdrawn
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
NCT02288481
Condition: Tuberculosis
Interventions: Drug: TBA-354; Other: Placebo
Sponsor: Global Alliance for TB Drug Development
Completed
PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)
NCT02216331
Condition: Tuberculosis
Interventions: Drug: TMC207; Drug: rifapentine; Drug: rifampicin
Sponsor: Global Alliance for TB Drug Development
Completed
TD-9855 Mass Balance Study
NCT01924143
Conditions: ADHD; Fibromyalgia
Intervention: Drug: TD-9855
Sponsor: Theravance Biopharma
Completed
Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009)
NCT01830439
Condition: Tuberculosis
Interventions: Drug: PA-824 200mg; Drug: PA-824 50mg
Sponsor: Global Alliance for TB Drug Development
Completed
Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam
NCT01768273
Condition: Tuberculosis
Interventions: Drug: Midazolam; Drug: PA-824
Sponsor: Global Alliance for TB Drug Development
Completed
Sufentanil Infusion vs Sufentanil Bolus
NCT04226495
Condition: Anesthesia
Interventions: Drug: Sufentanil Infusion; Drug: Sufentanil Bolus
Sponsor: University of Nebraska
Not yet recruiting
Sustaining the Reach of a Scalable Weight Loss Intervention Through Financial Incentives
NCT04225234
Condition: Overweight and Obesity
Intervention: Other: Financial incentives
Sponsor: University of Nebraska
Recruiting
A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease
NCT04222062
Condition: Brain Tumor - Metastatic
Intervention: Drug: Carmustine 7.7Mg Wafer
Sponsors: Michele Aizenberg, MD; Arbor Pharmaceuticals, Inc.
Not yet recruiting
Pilot Study- Treat to Target Vitamin D in End Stage Renal Disease
NCT04167111
Condition: Chronic Kidney Diseases
Intervention: Dietary Supplement: Cholecalciferol
Sponsors: University of Nebraska; University of Nebraska, Omaha
Not yet recruiting
Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYNOTE-01C)
NCT04165096
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: Pembrolizumab; Biological: MK-5890
Sponsor: Merck Sharp & Dohme Corp.
Recruiting
Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYNOTE-01A)
NCT04165070
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pemetrexed; Biological: MK-7684
Sponsor: Merck Sharp & Dohme Corp.
Recruiting
A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
NCT04083651
Condition: Pancreatic Cancer
Interventions: Drug: Methylnaltrexone bromide; Drug: Placebo
Sponsor: Bausch Health Americas, Inc.
Recruiting
Uphill Walking as Exercise for COPD Patients
NCT04026529
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Other: walking on incline or walking at increasing speed
Sponsors: VA Office of Research and Development; University of Nebraska, Omaha
Not yet recruiting
Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE
NCT03998176
Condition: HIV-1-infection
Intervention: Drug: Bictegravir/emtricitabine/tenofovir alafenamide
Sponsors: University of Nebraska; Gilead Sciences
Recruiting
Evaluation of the Spry Belt for Improving Bone Quality
NCT03986203
Condition: Osteopenia
Intervention: Device: Spry Belt
Sponsors: Theranova, L.L.C.; National Institute on Aging (NIA); University of Nebraska
Recruiting
A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants
NCT03961295
Condition: Healthy Volunteers
Intervention: Drug: Vedolizumab SC
Sponsor: Takeda
Completed
Impact of Evolocumab in Cardiac Transplant Patients With CAV
NCT03944577
Condition: Heart Transplant
Intervention: Drug: Evolocumab (Repatha)
Sponsors: University of Nebraska; Amgen
Recruiting
ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant
NCT03932643
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes
Intervention: Drug: ONC201
Sponsor: Vijaya Bhatt
Recruiting
Restoring Cognitive Control in Acute Nicotine Withdrawal
NCT03887429
Condition: Impulse Control Disorders
Interventions: Drug: SXC-2023; Drug: Placebos
Sponsors: Promentis Pharmaceuticals, Inc.; Baylor College of Medicine; Celerion
Completed
Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults
NCT03858075
Condition: Healthy Volunteers
Interventions: Drug: BLU-782; Drug: Placebo; Drug: BLU-782 taken with food
Sponsor: Blueprint Medicines Corporation
Completed
Restoration of Spectral Resolution With Hearing-aid Amplification
NCT03850678
Condition: Hearing Loss
Intervention: Device: Hearing Aid
Sponsors: University of Nebraska Lincoln; National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting
Biomarker Assessments of Leukine During Treatment of Parkinson's Disease
NCT03790670
Condition: Parkinson Disease
Intervention: Drug: sargramostim
Sponsor: University of Nebraska
Active, not recruiting
Effect of Vitamin D Supplementation on Balance in CKD
NCT03710161
Conditions: Renal Insufficiency, Chronic; Kidney Failure, Chronic
Intervention: Drug: Vitamin D
Sponsor: University of Nebraska
Recruiting
Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
NCT03662295
Conditions: Migraine Disorders; Aphasia
Intervention: Behavioral: Language treatment
Sponsor: Quality Living, Inc.
Completed
Targeted Transcranial Magnetic Stimulation to Improve Hippocampal-dependent Declarative Memory Abilities
NCT03574207
Conditions: Mild Cognitive Impairment; Memory Loss
Intervention: Device: Transcranial magnetic stimulation
Sponsors: University of Nebraska; National Institute of General Medical Sciences (NIGMS)
Recruiting
Dietary Nitrate Supplementation and Thermoregulation
NCT03506646
Conditions: Peripheral Arterial Disease; Peripheral Artery Disease
Intervention: Dietary Supplement: Beetroot juice
Sponsor: University of Nebraska, Omaha
Recruiting
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
NCT03506633
Conditions: Peripheral Arterial Disease; Peripheral Artery Disease
Intervention: Dietary Supplement: MitoQ
Sponsor: University of Nebraska, Omaha
Recruiting
Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
NCT03476174
Condition: Melanoma
Interventions: Drug: Pembrolizumab; Drug: Interleukin-2
Sponsors: Ralph Hauke; Nebraska Cancer Specialists; Midwest Cancer Center-Legacy; Prometheus Laboratories
Terminated
Bisphosphonates for Prevention of Post-Denosumab Bone Loss
NCT03396315
Conditions: IOP; Osteoporosis
Interventions: Drug: Alendronate; Drug: Zoledronic Acid
Sponsors: Columbia University; Amgen
Recruiting
Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer
NCT03386500
Conditions: Anal Cancer, Squamous Cell Carcinoma; Radiation Exposure
Intervention: Drug: BMX-001
Sponsors: Chi Lin, MD; BioMimetix JV, LLC; University of Nebraska
Recruiting
Engaging Rural Men With Mobile Technologies for Weight Loss
NCT03329079
Condition: Weight Loss
Interventions: Behavioral: Mobile Technology Plus; Behavioral: Mobile Technology
Sponsors: University of Nebraska; Northeast Nebraska Public Health Department
Active, not recruiting
Language Assessment and Treatment Following Acquired Brain Injury
NCT03320954
Condition: Brain Injuries
Intervention: Behavioral: Anomia treatment
Sponsor: University of Nebraska Lincoln
Completed
Preventing Diabetes With Digital Health and Coaching
NCT03312764
Condition: PreDiabetes
Interventions: Behavioral: Online diabetes prevention program; Behavioral: Standard Care
Sponsors: Omada Health, Inc.; University of Nebraska; Wake Forest University Health Sciences
Active, not recruiting
Impact of Oral Hygiene Gels on Peri-implant Mucositis
NCT03243591
Condition: Mucositis
Interventions: Other: Livionex gel; Other: Aquafresh gel
Sponsor: University of Nebraska
Completed
Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults With Acute Myeloid Leukemia
NCT03226418
Conditions: Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Drug: Decitabine; Drug: Idarubicin; Other: Laboratory Biomarker Analysis; Drug: Liposome-encapsulated Daunorubicin-Cytarabine; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Drug: Azacitidine; Drug: Venetoclax; Drug: glasdegib
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Recruiting
Efficacy of Synthetic Bone Graft for Treatment of Peri-implantitis
NCT03213210
Condition: Peri-Implantitis
Intervention: Device: easy-graft CLASSIC (beta-Tricalcium Phosphate)
Sponsor: Sunstar Americas
Recruiting
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02874404
Conditions: Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Ibrutinib; Other: Laboratory Biomarker Analysis; Drug: PI3K-delta Inhibitor TGR-1202
Sponsors: Matthew Lunning, DO; National Cancer Institute (NCI)
Completed
Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
NCT02833701
Conditions: Glioblastoma; Glioma
Interventions: Dietary Supplement: Ascorbic Acid; Biological: Bevacizumab; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Terminated
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
NCT02767388
Conditions: Myelodysplastic Syndrome; Effects of Chemotherapy; Mild Cognitive Impairment; Multiple Myeloma; Non-hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Acute Lymphoid Leukemia; Chronic Myeloid Leukemia; Acute Myeloid Leukemia
Intervention:
Sponsor: University of Nebraska
Completed
Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics
NCT02759861
Condition: Genotype 1 Hepatitis C Virus
Intervention: Drug: harvoni
Sponsor: University of Nebraska
Active, not recruiting
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
NCT02700841
Condition: Plasma Cell Myeloma
Interventions: Drug: Melphalan; Procedure: Peripheral Blood Stem Cell Transplantation--CD34 HSCT; Procedure: Peripheral Blood Stem Cell Transplantation--AHSCT; Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation; Biological: Tetanus Toxoid Vaccine
Sponsor: University of Nebraska
Suspended
Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia
NCT02647892
Condition: Local Anesthesia
Interventions: Drug: lidocaine; Drug: sodium bicarbonate
Sponsor: University of Nebraska
Enrolling by invitation
Cholecalciferol in Treating Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency
NCT02553447
Conditions: Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma; Untreated Chronic Lymphocytic Leukemia; Vitamin D Deficiency
Interventions: Dietary Supplement: Cholecalciferol; Other: Laboratory Biomarker Analysis
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Recruiting
Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12-36 Months of Age With Serologic Evidence of Prior Exposure
NCT04144348
Condition: Human Metapneumovirus and Human Parainfluenza Infection
Interventions: Biological: mRNA-1653; Biological: Placebo
Sponsor: ModernaTX, Inc.
Recruiting
Phase 1 Study of ACE-083 in Healthy Subjects
NCT02257489
Condition: Musculoskeletal Diseases
Intervention: Drug: ACE-083
Sponsor: Acceleron Pharma, Inc.
Completed
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
NCT02049866
Condition: Adult Idiopathic Generalized Osteoporosis
Intervention: Drug: Denosumab
Sponsors: Elizabeth Shane; Creighton University
Active, not recruiting
Measurement of Beta Cell Death in Individuals With Cystic Fibrosis
NCT03713437
Condition: Cystic Fibrosis-related Diabetes
Intervention: Diagnostic Test: Measurement of differentially methylated insulin DNA
Sponsors: University of Nebraska; Cystic Fibrosis Foundation
Recruiting
Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer
NCT01959672
Conditions: Pancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma; Stage I Pancreatic Cancer; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage II Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer
Interventions: Procedure: 4-Dimensional Computed Tomography; Drug: Fluorouracil; Drug: Gemcitabine Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Nelfinavir Mesylate; Biological: Oregovomab; Radiation: Stereotactic Body Radiation Therapy; Procedure: Therapeutic Conventional Surgery
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Completed
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
NCT03574584
Conditions: Metabolism and Nutrition Disorders; Overweight or Obesity
Interventions: Drug: NNC0165-1562; Drug: Semaglutide; Drug: Placebo (NNC0165-1562)
Sponsor: Novo Nordisk A/S
Completed
Effects of Octacosanol During Taekwondo Training
NCT03557476
Conditions: Oxidative Stress; Dyslipidemias
Interventions: Dietary Supplement: Octacosanol; Dietary Supplement: Placebo
Sponsor: University of Nebraska, Omaha
Completed
Mobility Exercises for Gait (MEG Neuroplasticity Project)
NCT03555708
Condition: Cerebral Palsy
Intervention: Other: Physical Therapy
Sponsor: University of Nebraska
Recruiting
Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp
NCT01930539
Conditions: Vitamin D Deficiency; Short Bowel Syndrome
Intervention: Device: Ultraviolet B lamp
Sponsor: University of Nebraska
Completed
Cardiac Allograft Remodeling and Effects of Sirolimus
NCT01889992
Conditions: Cardiac Hypertrophy; Immunosuppression
Interventions: Radiation: Cardiac MRI; Procedure: Coronary angiography with IVUS; Other: Cardiac Allograft Remodeling; Drug: M-TOR Immunosuppression; Procedure: Cardiac Biopsy C4D stain; Genetic: Genetic Mechanism of M-TOR; Other: Cardiopulmonary Exercise Test (CPET)
Sponsor: University of Nebraska
Suspended
Resurgence as Choice: Basic and Clinical Studies
NCT03423940
Conditions: Increasing Functional Communicative Behavior; Decreasing Destructive Behavior; Analysis of Treatment Dosage; Empirically Determined Reinforcement Schedule Thinning
Interventions: Behavioral: Functional communication training; Behavioral: RaC-enhanced functional communication training
Sponsors: Rutgers, The State University of New Jersey; Utah State University
Recruiting
Feasibility of a Touch Screen Computer Based Breast-feeding Educational Support Program
NCT03308058
Condition: Pregnancy Related
Intervention: Behavioral: Breastfeeding computer education
Sponsor: University of Nebraska
Completed
Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women
NCT01440803
Condition: Adult Idiopathic Generalized Osteoporosis
Interventions: Drug: Teriparatide; Drug: Saline Placebo
Sponsors: Elizabeth Shane; Food and Drug Administration (FDA)
Completed
Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer
NCT01307956
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Adenocarcinoma; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer
Interventions: Drug: Fluorouracil; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Biological: Panitumumab; Other: Pharmacological Study; Radiation: Radiation Therapy; Procedure: Therapeutic Conventional Surgery
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Terminated
Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control
NCT02483572
Conditions: Aggression; Self-Injurious Behavior
Intervention: Behavioral: Functional Communication Training
Sponsor: University of Nebraska
Terminated
Stereotactic Radiation Therapy, Nelfinavir Mesylate, Gemcitabine Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Locally Advanced Pancreatic Cancer
NCT01068327
Conditions: Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: leucovorin calcium; Drug: fluorouracil; Drug: nelfinavir mesylate; Radiation: stereotactic body radiation therapy; Radiation: hypofractionated radiation therapy; Procedure: therapeutic conventional surgery
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Completed
Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
NCT01052051
Condition: Cancer
Interventions: Dietary Supplement: Vitamin D3; Dietary Supplement: Calcium carbonate
Sponsors: Creighton University; National Institutes of Health (NIH); National Cancer Institute (NCI)
Completed
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
NCT00856037
Condition: Recurrent Small Cell Lung Carcinoma
Interventions: Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Drug: Topotecan Hydrochloride
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Completed
Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders
NCT01867398
Conditions: Conduct Disorder; fMRI
Intervention:
Sponsors: National Institute of Mental Health (NIMH); Boys Town Research Hospital
Terminated
Relationship Between Physical Activity and Stem Cells in Older Adults
NCT00690183
Condition: Aging
Intervention:
Sponsor: University of Nebraska
Completed
Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison
NCT00626366
Condition: Chronic Sinusitis
Interventions: Radiation: Sinus CT Scan; Drug: Omnipaque 240 Contrast Solution; Drug: Omnipaque 240 mg I/mL
Sponsor: University of Nebraska
Completed
CT Scans in Screening for Lung Cancer in Current and Former Smokers
NCT00625690
Condition: Lung Cancer
Interventions: Other: questionnaire administration; Procedure: computed tomography; Procedure: evaluation of cancer risk factors; Procedure: study of high risk factors
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Completed
Role of Apathy in the Effectiveness of Weight Loss Interventions
NCT00548652
Conditions: Obesity; Apathy
Interventions: Behavioral: MOVE; Behavioral: medical crisis councelling; Drug: methyphenidate
Sponsor: VA Nebraska Western Iowa Health Care System
Completed
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
NCT00089024
Condition: Pancreatic Cancer
Interventions: Drug: fluorouracil; Drug: gemcitabine hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: radiation therapy
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Completed
Validity of Physical Activity Questionnaires in Persons Pursuing Bariatric Surgery
NCT03981978
Conditions: Bariatric Surgery Candidate; Obesity
Intervention: Behavioral: Physical Activity
Sponsor: University of Nebraska
Not yet recruiting
Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic
NCT03431831
Condition: Obesity
Interventions: Behavioral: Intervention Control; Behavioral: Counselling; Drug: Contrave; Drug: Contrave and Counseling
Sponsor: University of Nebraska
Active, not recruiting
Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics
NCT01994174
Condition: Macular Disease
Intervention:
Sponsor: University of Nebraska
Recruiting
Bupropion in the Treatment of Methamphetamine Dependence
NCT00572234
Condition: Methamphetamine Use Disorder
Intervention: Drug: bupropion SR
Sponsor: University of Nebraska
Completed
First-Sight Refractive Error Correction: Direct Comparison to Autorefraction Results in Children 7 to 18 Years of Age
NCT01365884
Condition: Refractive Error
Intervention:
Sponsor: University of Nebraska
Terminated
Pain Management Following Sinus Surgery
NCT03822962
Conditions: Nasal Sinus; Inflammation; Opioid Abuse; Pain, Postoperative
Interventions: Drug: Ibuprofen 600Mg Tablet; Other: Standard Regimen | Tylenol
Sponsor: University of Nebraska
Recruiting
Umbrella Master Protocol: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYNOTE-U01)
NCT04165798
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Diagnostic Test: Tumor Imaging; Procedure: Tumor Tissue Collection; Procedure: Blood Sample Collection
Sponsor: Merck Sharp & Dohme Corp.
Recruiting
A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants
NCT03961308
Condition: Healthy Volunteers
Intervention: Drug: Vedolizumab SC
Sponsor: Takeda
Completed
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery
NCT02654119
Conditions: HER2 Positive Breast Carcinoma; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7
Interventions: Drug: Cyclophosphamide; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Biological: Trastuzumab
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Active, not recruiting
An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers
NCT03882359
Condition: Heart Diseases
Interventions: Diagnostic Test: Echocardiogram; Drug: MVT-100; Drug: Definity
Sponsors: Microvascular Therapeutics, LLC; National Heart, Lung, and Blood Institute (NHLBI); University of Nebraska
Recruiting
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
NCT03737123
Condition: Urothelial Carcinoma
Interventions: Drug: Carboplatin; Drug: Gemcitabine; Drug: Atezolizumab; Drug: Docetaxel
Sponsors: Nabil Adra; Genentech, Inc.; Indiana University School of Medicine
Recruiting
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
NCT03007979
Conditions: Breast Cancer; Breast Carcinoma; Cancer of Breast; Malignant Tumor of Breast
Interventions: Drug: Palbociclib; Drug: Letrozole; Drug: Fulvestrant; Procedure: Optional research biopsy; Drug: Goserelin; Procedure: Research blood draw; Procedure: Circulating tumor cell blood draw; Procedure: Tumor biopsy (optional)
Sponsors: Washington University School of Medicine; Pfizer
Recruiting
Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults
NCT03392389
Condition: Human Metapneumovirus and Human Parainfluenza Infection
Interventions: Biological: mRNA-1653; Other: Placebo
Sponsor: ModernaTX, Inc.
Active, not recruiting
Study on Physical Activity's Relationship With Cancer and Cognition
NCT03980626
Conditions: Breast Cancer; Breast Neoplasm Female
Intervention: Behavioral: Walking
Sponsor: University of Nebraska
Recruiting
Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO
NCT03673566
Conditions: Preterm Birth; Low; Birthweight, Extremely (999 Grams or Less); Neonatal Infection; Satisfaction; Stress; Chronic Lung Disease; Growth Acceleration; Adverse Event
Intervention: Device: NICU Dashboard
Sponsors: Philips Healthcare; Children's Hospital and Medical Center, Omaha, Nebraska
Recruiting
Treatment for Reading and Writing Deficits Following Acquired Brain Injury
NCT03662243
Conditions: Acquired Brain Injury; Alexia; Agraphia
Intervention: Behavioral: Multicomponent reading and writing treatment
Sponsor: Quality Living, Inc.
Enrolling by invitation
Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis
NCT03010228
Condition: Lyme Borreliosis, Nervous System
Interventions: Biological: VLA15 with Alum; Biological: VLA15 without Alum
Sponsor: Valneva Austria GmbH
Completed
Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis
NCT00826020
Conditions: Parenteral Nutrition Associated Liver Disease PNALD; Cholestasis
Intervention: Drug: Omegaven™
Sponsor: University of Nebraska
Completed
Safety Study of Oral Edaravone Administered in Subjects With ALS
NCT04165824
Condition: ALS
Intervention: Drug: MT-1186
Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
Recruiting
Self-Management App for Patients With Left-Ventricular Assist Devices
NCT03049748
Condition: Heart Failure
Interventions: Device: Mobile phone app (VAD Care App); Other: Usual LVAD Care
Sponsors: University of Michigan; Washington University School of Medicine; National Institute of Nursing Research (NINR)
Completed
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
NCT02062632
Conditions: Esophageal Carcinoma; Hypopharyngeal Carcinoma; Laryngeal Carcinoma; Lymphoma; Mesothelioma; Metastatic Malignant Neoplasm in the Lung; Metastatic Malignant Neoplasm in the Pleura; Metastatic Malignant Neoplasm in the Spinal Cord; Non-Small Cell Lung Carcinoma; Sarcoma; Small Cell Lung Carcinoma; Thymic Carcinoma; Thymoma; Thyroid Gland Carcinoma
Interventions: Drug: Doxepin Hydrochloride; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Terminated
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
NCT03598998
Conditions: Anaplastic Large Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Hepatosplenic T-Cell Lymphoma; Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma; Recurrent Mycosis Fungoides; Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified; Refractory Anaplastic Large Cell Lymphoma; Refractory Angioimmunoblastic T-Cell Lymphoma; Refractory Enteropathy-Associated T-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Hepatosplenic T-Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified; Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions: Biological: Pembrolizumab; Drug: Pralatrexate
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting
Venetoclax in Treating Participants With Recurrent or Refractory Mature T-Cell Lymphoma
NCT03534180
Conditions: Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Interventions: Other: Laboratory Biomarker Analysis; Drug: Venetoclax
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting
Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
NCT01789320
Conditions: Uveitis; Intermediate Uveitis; Posterior Uveitis; Panuveitis; Noninfectious Uveitis
Intervention: Drug: triamcinolone acetonide (Triesence®)
Sponsor: Clearside Biomedical, Inc.
Completed
Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy
NCT01035463
Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation; Drug: Carmustine; Drug: Cytarabine; Drug: Etoposide; Drug: Lenalidomide; Drug: Melphalan; Biological: Rituximab
Sponsors: University of Nebraska; National Cancer Institute (NCI)
Completed
Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer
NCT01880528
Conditions: Dyspnea; Non-small Cell Lung Cancer; Small Cell Lung Cancer
Interventions: Drug: lisinopril; Drug: placebo
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Completed
Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma
NCT00717522
Condition: Soft Tissue Sarcoma
Intervention: Drug: Pomalidomide
Sponsor: Celgene
Terminated
Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
NCT04064905
Condition: Zika Virus
Interventions: Biological: mRNA-1893; Other: Placebo
Sponsors: ModernaTX, Inc.; Biomedical Advanced Research and Development Authority
Recruiting
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
NCT04067011
Condition: Anthrax
Interventions: Drug: Ciprofloxacin 500Mg Tablet; Drug: Doxycycline 100Mg Tablet; Biological: AV7909
Sponsors: Emergent Product Development Gaithersburg, Inc.; Biomedical Advanced Research and Development Authority
Recruiting
Validation of Patient Reported Outcome Measures for Use in Vulvodynia
NCT03770169
Condition: Vulvodynia
Intervention:
Sponsor: Ipsen
Completed
Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
NCT03616184
Condition: Graft-versus-host-disease (GVHD)
Intervention: Drug: Ruxolitinib
Sponsor: University of Nebraska
Recruiting
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
NCT02673255
Condition: Healthy
Intervention: Biological: Tetanus and Diphtheria (Td) Vaccine
Sponsors: Biomat USA, Inc.; Hammond Clinical Trial Consulting, LLC; Axio Research. LLC
Completed
Smith-Lemli-Opitz Syndrome and Cholic Acid
NCT03720990
Condition: Smith-Lemli-Opitz Syndrome
Intervention: Drug: Cholic Acid
Sponsors: University of Nebraska; University of Colorado, Denver; Children's Hospital Medical Center, Cincinnati; University of Pittsburgh
Not yet recruiting
A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
NCT02990468
Condition: Head and Neck Cancer
Interventions: Drug: BMX-001; Radiation: Radiation Therapy; Drug: Cisplatin
Sponsors: BioMimetix JV, LLC; Duke University
Active, not recruiting
A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas
NCT03316573
Conditions: Lymphoma; Histiocytic Sarcoma; Follicular Dendritic Cell Sarcoma; Interdigitating Dendritic Cell Sarcoma
Intervention: Drug: Pembrolizumab
Sponsors: Dana-Farber Cancer Institute; Merck Sharp & Dohme Corp.
Recruiting
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
NCT02967133
Conditions: Non-Small-Cell Lung Cancer Metastatic; Non-Small Cell Carcinoma of Lung, TNM Stage 4; Nonsmall Cell Lung Cancer; Non Small Cell Lung Cancer Recurrent
Interventions: Drug: Nivolumab; Drug: nab-paclitaxel
Sponsors: Alliance Foundation Trials, LLC.; Celgene Corporation; Bristol-Myers Squibb
Active, not recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus
NCT02445911
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: KQ-791; Drug: Placebo
Sponsor: Kaneq Bioscience Limited
Completed
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
NCT00477529
Condition: Hormone Refractory Prostate Cancer
Intervention: Drug: ABI-008
Sponsor: Celgene
Completed
A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
NCT04032093
Condition: Respiratory Tract Infection
Interventions: Biological: RSV vaccine; Biological: Placebo
Sponsor: Pfizer
Recruiting
Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
NCT03828617
Condition: Pneumococcal Disease
Interventions: Biological: 20vPnC; Biological: 13vPnC
Sponsor: Pfizer
Completed
LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
NCT03412890
Conditions: Heavy Menstrual Bleeding; Uterine Fibroid
Interventions: Drug: Relugolix; Drug: Estradiol/norethindrone acetate
Sponsor: Myovant Sciences GmbH
Active, not recruiting
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults
NCT03301051
Conditions: Virus Diseases; RNA Virus Infections; Respiratory Tract Diseases; Respiratory Tract Infections
Interventions: Biological: Quadrivalent VLP Vaccine; Biological: Placebo
Sponsor: Medicago
Completed
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
NCT03150693
Condition: B Acute Lymphoblastic Leukemia
Interventions: Drug: Allopurinol; Drug: Cytarabine; Drug: Daunorubicin Hydrochloride; Drug: Vincristine Sulfate; Drug: Dexamethasone; Drug: Pegylated L-Asparaginase; Drug: Methotrexate; Procedure: Bone Marrow Aspiration and Biopsy; Drug: Cyclophosphamide; Drug: Mercaptopurine; Biological: Rituximab; Drug: Doxorubicin; Drug: Thioguanine; Biological: Inotuzumab Ozogamicin; Other: Laboratory Biomarker Analysis
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
NCT03049735
Conditions: Heavy Menstrual Bleeding; Uterine Fibroid
Interventions: Drug: Relugolix; Drug: Estradiol/norethindrone acetate; Drug: Placebo for E2/NETA; Drug: Placebo for relugolix
Sponsor: Myovant Sciences GmbH
Active, not recruiting
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
NCT03311555
Condition: Prostate Cancer
Interventions: Drug: Apalutamide; Drug: Androgen deprivation; Radiation: Salvage radiation therapy; Drug: Docetaxel
Sponsor: Tian Zhang, MD
Recruiting
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
NCT02624947
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV F vaccine with adjuvant; Biological: Formulation buffer
Sponsors: Novavax; Bill and Melinda Gates Foundation
Completed
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
NCT03520517
Conditions: Amyotrophic Lateral Sclerosis; ALS; Lou Gehrig Disease; Lou Gehrig's Disease; Lou-Gehrigs Disease; Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Intervention: Drug: BHV-0223
Sponsors: Biohaven Pharmaceuticals, Inc.; Cognitive Research Corporation
Completed
Post Hoc Analysis and Clinical Data Collection for Subjects Tested With Brain Network Activation (BNA™) Technology
NCT03699514
Conditions: Healthy; Cognitive Impairment; Neurological Disorder
Intervention: Device: Brain Network Activation (BNA™) technology
Sponsor: ElMindA Ltd
Recruiting
Prospective Clinicogenomic Program
NCT04180176
Conditions: Non-Small Cell Lung Cancer (NSCLC); Small-Cell Lung Cancer (SCLC)
Intervention: Other: Blood Draw
Sponsors: Genentech, Inc.; Flatiron Health, Inc.; Foundation Medicine, Inc.
Recruiting
A Multicenter, Double-blind, Randomized, Controlled, Roll-over Retreatment Study of the Safety and Pain Associated With Injections of PN40082, RV001 With Topical Anesthetic or RV001 for Lip Augmentation
NCT04029545
Condition: Lip Augmentation
Intervention: Device: PN40082
Sponsors: Prollenium Medical Technologies Inc.; Symbio, LLC
Active, not recruiting
High Dose IL 2 and Entinostat in RCC
NCT03501381
Condition: Renal Cell Carcinoma
Interventions: Drug: Entinostat; Drug: Interleukin-2
Sponsors: Roberto Pili; Indiana University Melvin and Bren Simon Cancer Center; Prometheus Laboratories; Syndax Pharmaceuticals
Recruiting
Prostaglandin Inhibition for Emphysema
NCT02006576
Condition: Emphysema
Interventions: Drug: 600 mg ibuprofen three times daily for 48 weeks; Other: Placebo three times daily
Sponsors: University of Nebraska; National Jewish Health; Temple University; University of California, Los Angeles; University of Alabama at Birmingham
Completed
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer
NCT04095364
Conditions: Low Grade Ovarian Serous Adenocarcinoma; Primary Peritoneal Low Grade Serous Adenocarcinoma; Stage II Ovarian Cancer AJCC v8; Stage IIA Ovarian Cancer AJCC v8; Stage IIB Ovarian Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8
Interventions: Drug: Carboplatin; Drug: Letrozole; Drug: Paclitaxel
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT04094688
Condition: Colorectal Adenocarcinoma
Interventions: Drug: Bevacizumab; Drug: Oxaliplatin; Drug: Leucovorin Calcium; Drug: Fluorouracil; Drug: Irinotecan Hydrochloride; Drug: Irinotecan; Dietary Supplement: Cholecalciferol; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
NCT03971474
Conditions: Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Drug: Docetaxel; Drug: Gemcitabine; Drug: Gemcitabine Hydrochloride; Biological: Pembrolizumab; Drug: Pemetrexed; Drug: Pemetrexed Disodium; Biological: Ramucirumab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
NCT03984448
Conditions: Diffuse Large B-Cell Lymphoma; Double-Expressor Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Etoposide; Drug: Prednisone; Biological: Rituximab; Drug: Venetoclax; Drug: Vincristine; Drug: Vincristine Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
NCT03994796
Conditions: CDK Gene Mutation; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Solid Neoplasm; NTRK Family Gene Mutation; PI3K Gene Mutation; ROS1 Gene Mutation
Interventions: Drug: Abemaciclib; Drug: PI3K Inhibitor GDC-0084; Drug: Entrectinib
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Genentech, Inc.
Recruiting
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Condition: Smoldering Plasma Cell Myeloma
Interventions: Biological: Daratumumab; Drug: Dexamethasone; Drug: Lenalidomide; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Recruiting
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Condition: Previously Treated Non-Small Cell Lung Cancer
Intervention: Drug: Screening Platform
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT03866382
Conditions: Bladder Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Small Cell Carcinoma; Bladder Squamous Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Infiltrating Bladder Lymphoepithelioma-Like Carcinoma; Infiltrating Bladder Urothelial Carcinoma; Infiltrating Bladder Urothelial Carcinoma With Giant Cells; Infiltrating Bladder Urothelial Carcinoma, Nested Variant; Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant; Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant; Kidney Medullary Carcinoma; Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Carcinoma; Metastatic Bladder Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Small Cell Carcinoma; Metastatic Bladder Squamous Cell Carcinoma; Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Genitourinary System Neoplasm; Metastatic Penile Carcinoma; Metastatic Prostate Small Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IVA Bladder Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Bladder Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Testicular Leydig Cell Tumor; Testicular Sertoli Cell Tumor
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
NCT03793179
Conditions: Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8
Interventions: Drug: Carboplatin; Biological: Pembrolizumab; Drug: Pemetrexed
Sponsor: National Cancer Institute (NCI)
Recruiting
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
NCT03768414
Conditions: Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Nab-paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
NCT03793166
Conditions: Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Malignant Neoplasm in the Viscera; Sarcomatoid Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
Interventions: Drug: Cabozantinib; Biological: Ipilimumab; Biological: Nivolumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)
NCT03737994
Conditions: Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Drug: Alectinib; Drug: Brigatinib; Drug: Carboplatin; Drug: Ceritinib; Drug: Cisplatin; Drug: Crizotinib; Drug: Ensartinib; Drug: Lorlatinib; Drug: Pemetrexed
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer
NCT03811015
Conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions: Drug: Cisplatin; Radiation: Intensity-Modulated Radiation Therapy; Biological: Nivolumab; Other: Patient Observation
Sponsor: National Cancer Institute (NCI)
Recruiting
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29
Interventions: Other: Usual care disease monitoring; Other: Serum Tumor Marker directed disease monitoring; Other: Quality-of-Life Assessment; Other: Anxiety Questionnaire Administration
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
NCT03698019
Conditions: Acral Lentiginous Melanoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Mucosal Melanoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions: Biological: Pembrolizumab; Procedure: Therapeutic Conventional Surgery
Sponsor: National Cancer Institute (NCI)
Recruiting
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
NCT03701282
Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib; Biological: Obinutuzumab; Other: Quality-of-Life Assessment; Drug: Venetoclax
Sponsor: National Cancer Institute (NCI)
Recruiting
Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
NCT03694002
Conditions: Locally Advanced Thymic Carcinoma; Metastatic Thymic Carcinoma; Recurrent Thymic Carcinoma; Unresectable Thymic Carcinoma
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Biological: Ramucirumab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer
NCT03660826
Conditions: Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma; Stage IV Uterine Corpus Cancer AJCC v7; Stage IVA Uterine Corpus Cancer AJCC v7; Stage IVB Uterine Corpus Cancer AJCC v7
Interventions: Drug: Cediranib; Drug: Cediranib Maleate; Drug: Olaparib
Sponsors: National Cancer Institute (NCI); NRG Oncology
Active, not recruiting
Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
NCT03654768
Condition: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Drug: Dasatinib; Other: Laboratory Biomarker Analysis; Drug: Nilotinib; Drug: Ruxolitinib Phosphate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
NCT03839940
Condition: Malignant Neoplasm
Interventions: Drug: Dexamethasone; Other: Placebo; Other: Questionnaire; Other: Quality-of-Life Assessment; Drug: Everolimus
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Pembrolizumab and Epacadostat in Treating Patients With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma
NCT03602586
Conditions: Malignant Ovarian Clear Cell Tumor; Recurrent Ovarian Carcinoma
Interventions: Drug: Epacadostat; Biological: Pembrolizumab
Sponsors: National Cancer Institute (NCI); NRG Oncology
Suspended
Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
NCT03609216
Conditions: Infiltrating Bladder Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma; Stage III Bladder Urothelial Carcinoma
Interventions: Drug: Gemcitabine Hydrochloride; Drug: Cisplatin; Biological: Pegfilgrastim; Procedure: Conventional Surgery; Procedure: Radical Cystectomy; Other: Chemoradiotherapy
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
NCT03468985
Conditions: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Active, not recruiting
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT03414970
Conditions: Ductal Breast Carcinoma; Invasive Breast Carcinoma; Lobular Breast Carcinoma; Medullary Breast Carcinoma; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Tubular Breast Carcinoma
Interventions: Radiation: Radiation Therapy; Other: Questionnaire Administration; Other: Quality-of-Life Assessment; Other: Laboratory Biomarker Analysis; Radiation: Hypofractionated Radiation Therapy
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03418961
Conditions: Cardiotoxicity; HER2/Neu Positive; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Drug: Carvedilol; Other: Laboratory Biomarker Analysis; Other: Patient Observation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
NCT03382561
Conditions: Extensive Stage Lung Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma
Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Active, not recruiting
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
NCT03578081
Condition: Malignant Neoplasm
Interventions: Drug: Palonosetron Hydrochloride; Drug: Ondansetron Hydrochloride; Drug: Dexamethasone; Drug: Fosaprepitant Dimeglumine; Drug: Olanzapine; Other: Placebo
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711
Conditions: Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Anal Margin Squamous Cell Carcinoma; Stage IIB Anal Cancer AJCC v8; Stage IIIA Anal Cancer AJCC v8; Stage IIIB Anal Cancer AJCC v8; Stage IIIC Anal Cancer AJCC v8
Interventions: Biological: Nivolumab; Other: Patient Observation
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
NCT03228537
Conditions: Biphasic Mesothelioma; Epithelioid Mesothelioma; Stage I Pleural Malignant Mesothelioma AJCC v7; Stage IA Pleural Malignant Mesothelioma AJCC v7; Stage IB Pleural Malignant Mesothelioma AJCC v7; Stage II Pleural Malignant Mesothelioma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7
Interventions: Drug: Atezolizumab; Drug: Cisplatin; Procedure: Extrapleural Pneumonectomy; Drug: Pemetrexed Disodium; Procedure: Pleurectomy; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
NCT03087708
Conditions: Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: Naloxegol; Other: Placebo; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT03092674
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts-2
Interventions: Drug: Azacitidine; Drug: Cytarabine; Drug: Decitabine; Other: Laboratory Biomarker Analysis; Drug: Midostaurin; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Suspended
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
NCT03033576
Conditions: Advanced Melanoma; Melanoma of Unknown Primary; Mucosal Melanoma; Refractory Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Cutaneous Melanoma; Unresectable Melanoma
Interventions: Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
NCT03018249
Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma; FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma; FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma; Uterine Corpus Adenosarcoma
Interventions: Drug: Entinostat; Procedure: Hysterectomy; Other: Laboratory Biomarker Analysis; Drug: Medroxyprogesterone Acetate
Sponsors: National Cancer Institute (NCI); NRG Oncology
Active, not recruiting
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
NCT03518034
Conditions: Hypogonadism; Cardiovascular Diseases
Interventions: Drug: Testosterone; Drug: Placebo
Sponsors: AbbVie; Acerus Pharmaceuticals Corporation; Allergan Sales, LLC; Endo Pharmaceuticals; Upsher-Smith Laboratories
Recruiting
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
NCT03492281
Condition: Overactive Bladder
Interventions: Drug: vibegron; Drug: Placebos; Drug: Tolterodine Tartrate ER
Sponsor: Urovant Sciences GmbH
Completed
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
NCT02927249
Condition: Node Positive HER2 Negative Breast Cancer
Interventions: Other: Placebo; Drug: Aspirin
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group
Recruiting
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
NCT02921256
Conditions: Rectal Adenocarcinoma; Stage II Rectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7
Interventions: Drug: Capecitabine; Drug: Fluorouracil; Radiation: Intensity-Modulated Radiation Therapy; Drug: Leucovorin; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Biological: Pembrolizumab; Drug: Veliparib
Sponsors: National Cancer Institute (NCI); NRG Oncology
Suspended
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559
Conditions: Colon Adenocarcinoma; DNA Repair Disorder; Lynch Syndrome; Stage III Colon Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7
Interventions: Drug: Atezolizumab; Drug: Fluorouracil; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Recruiting
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
NCT02890355
Conditions: Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions: Drug: Fluorouracil; Drug: Irinotecan Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Veliparib
Sponsor: National Cancer Institute (NCI)
Active, not recruiting
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
NCT02893930
Conditions: Pancreatic Neuroendocrine Tumor G1; Pancreatic Neuroendocrine Tumor G2; Refractory Pancreatic Neuroendocrine Carcinoma
Intervention: Drug: Sapanisertib
Sponsor: National Cancer Institute (NCI)
Active, not recruiting
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02839707
Conditions: Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Undifferentiated Carcinoma; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Undifferentiated Carcinoma; Platinum-Resistant Ovarian Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Atezolizumab; Biological: Bevacizumab; Drug: Pegylated Liposomal Doxorubicin Hydrochloride; Other: Quality-of-Life Assessment
Sponsors: National Cancer Institute (NCI); NRG Oncology
Suspended
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer
NCT03304639
Conditions: Advanced Merkel Cell Carcinoma; Metastatic Merkel Cell Carcinoma; Stage III Merkel Cell Carcinoma AJCC v7; Stage IIIA Merkel Cell Carcinoma AJCC v7; Stage IIIB Merkel Cell Carcinoma AJCC v7; Stage IV Merkel Cell Carcinoma AJCC v7
Interventions: Biological: Pembrolizumab; Radiation: Stereotactic Body Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Active, not recruiting
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT02785952
Conditions: Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Active, not recruiting
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
NCT02954874
Conditions: Invasive Breast Carcinoma; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Other: Patient Observation; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826
Condition: Breast Carcinoma
Interventions: Other: Health Education Program; Other: Weight Loss Intervention
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group
Recruiting
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537
Conditions: Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant; Lip and Oral Cavity Squamous Cell Carcinoma; p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oral Cavity Verrucous Carcinoma; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Drug: Cisplatin; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Recruiting
Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
NCT02761057
Conditions: Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Drug: Crizotinib; Drug: Savolitinib; Drug: Sunitinib; Drug: Sunitinib Malate
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Active, not recruiting
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
NCT02601209
Conditions: High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Metastatic Unresectable Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8; Stage IV Uterine Corpus Leiomyosarcoma AJCC v8; Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8; Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8; Unresectable Leiomyosarcoma
Interventions: Drug: Pazopanib; Drug: Pazopanib Hydrochloride; Drug: Sapanisertib
Sponsor: National Cancer Institute (NCI)
Active, not recruiting
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
NCT02595905
Conditions: Breast Carcinoma Metastatic in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma
Interventions: Drug: Cisplatin; Other: Laboratory Biomarker Analysis; Other: Placebo Administration; Drug: Veliparib
Sponsor: National Cancer Institute (NCI)
Active, not recruiting
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT02562716
Conditions: Pancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma
Interventions: Drug: Fluorouracil; Drug: Gemcitabine Hydrochloride; Drug: Irinotecan Hydrochloride; Drug: Oxaliplatin; Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure: Pancreatectomy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Active, not recruiting
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
NCT02523014
Conditions: Intracranial Meningioma; Recurrent Meningioma; NF2 Gene Mutation
Interventions: Drug: vismodegib; Drug: GSK2256098
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); GlaxoSmithKline; Genentech, Inc.; Brain Science Foundation
Suspended
High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506153
Conditions: Metastatic Cutaneous Melanoma; Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Cutaneous Melanoma; Recurrent Non-Cutaneous Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage III Mucosal Melanoma of the Head and Neck AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7; Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7; Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7
Interventions: Biological: Ipilimumab; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Biological: Recombinant Interferon Alfa-2b
Sponsor: National Cancer Institute (NCI)
Active, not recruiting
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
NCT02500797
Conditions: Dedifferentiated Liposarcoma; Gastrointestinal Stromal Tumor; Locally Advanced Bone Sarcoma; Locally Advanced Soft Tissue Sarcoma; Metastatic Bone Sarcoma; Metastatic Liposarcoma; Metastatic Soft Tissue Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Metastatic Unresectable Sarcoma; Pleomorphic Liposarcoma; Stage III Bone Sarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Bone Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Bone Sarcoma AJCC v7; Stage IVB Bone Sarcoma AJCC v7; Unresectable Bone Sarcoma; Unresectable Liposarcoma; Unresectable Soft Tissue Sarcoma
Interventions: Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Active, not recruiting
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02498600
Conditions: Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Biological: Ipilimumab; Biological: Nivolumab
Sponsors: National Cancer Institute (NCI); NRG Oncology
Active, not recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967
Conditions: Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060
Conditions: Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Kidney Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Neoplasm; Melanoma; Ovarian Carcinoma; Pancreatic Carcinoma; Plasma Cell Myeloma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Plasma Cell Myeloma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Recurrent Uterine Corpus Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma; Uterine Corpus Cancer
Interventions: Drug: Adavosertib; Drug: Afatinib; Drug: Afatinib Dimaleate; Drug: Binimetinib; Drug: Capivasertib; Drug: Copanlisib; Drug: Copanlisib Hydrochloride; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Drug: Dasatinib; Drug: Defactinib; Drug: Defactinib Hydrochloride; Drug: Erdafitinib; Drug: FGFR Inhibitor AZD4547; Drug: Ipatasertib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Drug: Larotrectinib Sulfate; Biological: Nivolumab; Drug: Osimertinib; Drug: Palbociclib; Biological: Pertuzumab; Drug: PI3K-beta Inhibitor GSK2636771; Drug: Sapanisertib; Drug: Sunitinib Malate; Drug: Taselisib; Drug: Trametinib; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Drug: Ulixertinib; Drug: Vismodegib
Sponsor: National Cancer Institute (NCI)
Recruiting
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
NCT02445391
Conditions: Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma
Interventions: Drug: Capecitabine; Drug: Carboplatin; Drug: Cisplatin; Other: Laboratory Biomarker Analysis; Procedure: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Recruiting
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944
Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Intervention: Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Active, not recruiting
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
NCT02466971
Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Stage IB2 Cervical Cancer AJCC v6 and v7; Stage II Cervical Cancer AJCC v7; Stage II Vaginal Cancer AJCC v6 and v7; Stage IIA Cervical Cancer AJCC v7; Stage IIB Cervical Cancer AJCC v6 and v7; Stage III Vaginal Cancer AJCC v6 and v7; Stage IIIB Cervical Cancer AJCC v6 and v7; Stage IVA Cervical Cancer AJCC v6 and v7; Stage IVA Vaginal Cancer AJCC v6 and v7; Vaginal Adenocarcinoma; Vaginal Adenosquamous Carcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions: Drug: Cisplatin; Radiation: External Beam Radiation Therapy; Radiation: Intensity-Modulated Radiation Therapy; Radiation: Internal Radiation Therapy; Other: Laboratory Biomarker Analysis; Radiation: Radiation Therapy; Drug: Triapine
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
NCT02311933
Conditions: Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Tamoxifen Citrate; Drug: Z-Endoxifen Hydrochloride
Sponsor: National Cancer Institute (NCI)
Active, not recruiting
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
NCT02257528
Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Recurrent Cervical Carcinoma; Stage IV Cervical Cancer AJCC v6 and v7; Stage IVA Cervical Cancer AJCC v6 and v7; Stage IVB Cervical Cancer AJCC v6 and v7
Interventions: Other: Laboratory Biomarker Analysis; Biological: Nivolumab
Sponsors: National Cancer Institute (NCI); NRG Oncology
Active, not recruiting
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT02224781
Conditions: Metastatic Melanoma; Recurrent Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Cutaneous Melanoma
Interventions: Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Biological: Ipilimumab; Biological: Nivolumab; Other: Quality-of-Life Assessment; Drug: Trametinib; Drug: Trametinib Dimethyl Sulfoxide
Sponsor: National Cancer Institute (NCI)
Recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738
Conditions: Lung Adenocarcinoma; Lung Large Cell Carcinoma; Resectable Lung Non-Small Cell Carcinoma; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IB Lung Squamous Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage II Lung Squamous Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Squamous Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Squamous Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
Interventions: Other: Clinical Observation; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Erlotinib; Drug: Erlotinib Hydrochloride; Biological: Nivolumab; Other: Placebo Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282
Conditions: EGFR Exon 19 Deletion Mutation; EGFR NP_005219.2:p.L858R; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions: Other: Clinical Observation; Drug: Erlotinib; Drug: Erlotinib Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Placebo Administration
Sponsor: National Cancer Institute (NCI)
Recruiting

Menu

Categories

Recent Listings

Post your clinical trial on JoinClinicalTrials.com

JoinClinicalTrials.com

Omaha

Lincoln

Bellevue

Grand Island

Kearney

Fremont

Hastings

North Platte

Norfolk

Columbus

Yutan

Results

Post your clinical trial on JoinClinicalTrials.com

Popular Now